Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor

Wiley - Tập 40 Số 7 - Trang 285-300 - 2020
Yuqi Yang1, Ning Ji1,2, Chao‐Yun Cai1, Jing‐Quan Wang1, Zi‐Ning Lei1, Qiu‐Xu Teng1, Zhuo‐Xun Wu1, Qingbin Cui1,3, Yihang Pan4, Zhe‐Sheng Chen1
1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, 11439 USA
2State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Science and Peking Union Medical College, Institute of Hematology and Blood Diseases Hospital, Tianjin, 300020 P. R. China
3School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong, 511436 P. R. China
4Tomas Lindahl Nobel Laureate Laboratory, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518107 P. R. China

Tóm tắt

AbstractBackground

Overexpression of ATP‐binding cassette (ABC) transporter is a major contributor to multidrug resistance (MDR), in which cancer cells acquire resistance to a wide spectrum of chemotherapeutic drugs. In this work, we evaluated the sensitizing effect of sitravatinib, a broad‐spectrum tyrosine kinase inhibitor (TKI), on ATP‐binding cassette subfamily B member 1 (ABCB1)‐ and ATP‐binding cassette subfamily C member 10 (ABCC10)‐mediated MDR.

Methods

MTT assay was conducted to examine cytotoxicity and evaluate the sensitizing effect of sitravatinib at non‐toxic concentrations. Tritium‐labeled paclitaxel transportation, Western blotting, immunofluorescence analysis, and ATPase assay were carried out to elucidate the mechanism of sitravatinib‐induced chemosensitization. The in vitro findings were translated into preclinical evaluation with the establishment of xenograft models.

Results

Sitravatinib considerably reversed MDR mediated by ABCB1 and partially antagonized ABCC10‐mediated MDR. Our in silico docking simulation analysis indicated that sitravatinib strongly and stably bound to the transmembrane domain of ABCB1 human‐mouse chimeric model. Furthermore, sitravatinib inhibited hydrolysis of ATP and synchronously decreased the efflux function of ABCB1. Thus, sitravatinib could considerably enhance the intracellular concentration of anticancer drugs. Interestingly, no significant alterations of both expression level and localization of ABCB1 were observed. More importantly, sitravatinib could remarkably restore the antitumor activity of vincristine in ABCB1‐mediated xenograft model without observable toxic effect.

Conclusions

The findings in this study suggest that the combination of sitrvatinib and substrate antineoplastic drugs of ABCB1 could attenuate the MDR mediated by the overexpression of ABCB1.

Từ khóa


Tài liệu tham khảo

10.1038/nrc2789

10.1016/j.drup.2018.11.001

10.1007/978-1-60761-416-6_4

10.1016/j.drup.2014.11.002

10.1016/j.drup.2016.05.001

10.1158/0008-5472.CAN-17-2367

10.1186/s40880-019-0362-z

10.3389/fonc.2016.00175

10.1111/ijlh.12928

10.1186/s40880-019-0402-8

10.1208/s12248-015-9757-1

10.1038/nature05630

10.1023/A:1012823120935

10.1016/j.canlet.2017.07.023

10.1007/978-3-319-42934-2_6

10.1002/jcb.24533

10.1016/j.ejca.2017.01.001

10.7150/thno.21516

10.1016/j.leukres.2005.08.005

Zhang H, 2010, Reversion of multidrug resistance in tumor by biocompatible nanomaterials, Mini Rev Med Chem, 10, 737, 10.2174/138955710791572460

10.1016/j.clgc.2017.01.008

10.1007/s11255-017-1693-9

10.1111/jog.13493

TsukitaS OishiK AkiyamaT YamanashiY YamamotoT TsukitaSJTJoCB.Specific proto‐oncogenic tyrosine kinases of src family are enriched in cell‐to‐cell adherens junctions where the level of tyrosine phosphorylation is elevated.1991;113(4):867‐79.

PaimentA HockingJ WhitfieldCJJob.Impact of phosphorylation of specific residues in the tyrosine autokinase Wzc on its activity in assembly of group 1 capsules in Escherichia coli.2002;184(23):6437‐47.

10.1016/j.canlet.2018.10.032

10.18632/oncotarget.6547

Du W, 2018, Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, JCI insight, 3

10.1016/j.ejphar.2019.172611

10.1002/ijc.2910490512

10.1016/j.bcp.2019.05.015

10.1016/j.canlet.2018.02.040

10.1073/pnas.1717044115

Ji N, 2018, VS‐4718 Antagonizes Multidrug Resistance in ABCB1‐ and ABCG2‐Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters, Frontiers in Pharmacology, 9, 1236, 10.3389/fphar.2018.01236

10.1016/j.ejmech.2019.06.066

10.1021/acs.jmedchem.8b00335

10.3389/fonc.2019.00514

10.1016/j.bcp.2018.10.028

10.1186/s13045-016-0327-5

10.1111/bph.12889

Naito S, 1986, Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice, Cancer Res, 46, 4109

10.18632/oncotarget.6919

10.1007/BF00300234

10.1023/A:1012823120935

Cui Q, 2019, Glesatinib, a c‐MET/SMO Dual Inhibitor, Antagonizes P‐glycoprotein Mediated Multidrug Resistance in Cancer Cells, Frontiers in Oncology., 9, 313, 10.3389/fonc.2019.00313

10.1371/journal.pone.0220101

Mastri M, 2018, Tumor‐Independent Host Secretomes Induced By Angiogenesis and Immune‐Checkpoint Inhibitors, Mol Cancer Ther, 17, 1602, 10.1158/1535-7163.MCT-17-1066

10.2174/138945006777709520

10.1111/j.1742-4658.2011.08174.x

10.1016/j.chemphyslip.2009.07.004

Sonnino S, 2013, Membrane domains and the “lipid raft” concept, Curr Med Chem, 20, 4

Wu CP, 2020, Sitravatinib Sensitizes ABCB1‐ and ABCG2‐Overexpressing Multidrug‐Resistant Cancer Cells to Chemotherapeutic Drugs, Cancers, 12

Yang Y, 2020, Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy‐Resistant Cancer Cells in vitro, Frontiers in Oncology, 10

Thông tin
Thông tin xuất bản

Wiley

Tập 40 Số 7

285-300

Thông tin tác giả